Andere Sprachen Eton Pharmaceuticals, Inc.

Aktien

A2N38G

US29772L1089

ETON

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
3,45 ^USD	+10,58 %		+8,15 %	-21,23 %

22.03.	Sektor-Update: Aktien des Gesundheitswesens am Freitag vor der Glocke stabil	MT
22.03.	Sektor-Update: Gesundheitswesen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	17.04.
Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	15.04.
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE	25.03.
Bourse Zurich: en rouge pour finir la semaine "banques centrales"	22.03.
Sector Update: Health Care Stocks Steady Pre-Bell Friday	22.03.
Sector Update: Health Care	22.03.
Eton Pharmaceuticals Acquires U.S. Rights to PKU GOLIKE from Relief Therapeutics Holding SA	22.03.
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	22.03.
Relief Therapeutics trouve un partenaire de distribution US pour le Golike	22.03.
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	22.03.
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria	22.03.
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria	22.03.
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q4 Revenue $7.3M, vs. Street Est of $7.66M	14.03.
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	14.03.
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024	29.02.
Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent	21.02.
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	21.02.
Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	21.02.
Eton Pharmaceuticals Says Nitisinone Capsules Now Commercially Available in US	02.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Eton Pharmaceuticals, Inc.

Aktien

A2N38G

US29772L1089

ETON

Andere Sprachen

Filter